Humanigen Inc (fka HGENQ)

[DonDonDonDon]

I keep coming back to the 296% efficacy on preventing mechanical ventilation for early and mid stage severe patients under 85yo. And 217% efficacy on mortality for the same group. No other treatment has shown even good results for severe patients. Lenzilumab is a game changer. Every patient under 85yo should receive lenzilumab as soon as they become hospitalized.

[Lenzilumab improved the likelihood of SWOV] by 2.96-fold in subjects with CRP<150 mg/L and age <85 years (2.96; 1.63–5.37, nominal p=0.0003); and by 88% in subjects hospitalized ≤2 days prior to randomization (1.88; 1.13-3.12, nominal p=0.015). Survival was improved by 2.17-fold in subjects with CRP<150 mg/L and age <85 years (2.17; 1.04-4.54, nominal p=0.040).
https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1.full-text